Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in Pediatric Relapsed or Refractory Solid Tumors
NCT06941272Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 2 trial of patritumab deruxtecan in rhabdomyosarcoma (RMS), hepatoblastoma, sponsored by Merck & Co.. Started May 2025; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
rhabdomyosarcoma (RMS)hepatoblastoma
Beyond the preview
Go deeper on NCT06941272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941272.